Welcome To Diurnal

Diurnal is a UK-based specialty pharmaceutical company dedicated to developing high-quality hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism and Hypothyroidism.

The company has a strong, multi-skilled entrepreneurial management team with extensive pharmaceutical product development experience and an affiliated network of world-class clinical experts in the area of endocrinology.

Mission Statement

To address the major unmet clinical and patient needs in endocrinology by creating high quality products for the lifelong treatment of chronic conditions.

Latest News

  • 10 Jan

    Diurnal announces grant of second US patent for Chronocort®

    Method of treatment patent provides additional protection in key US market where Chronocort® has already received two Orphan Drug Designations

    Read More

  • 11 Dec

    Regulatory package for Chronocort® submitted for Scientific Advice in Europe

    Further analysis of data from European Chronocort® Phase III and safety extension study demonstrate significant benefits for patients sustained for at least 12 months

    Read More

  • 17 Oct

    Update on late-stage development pipeline

    Update on late-stage pipeline products for the replacement of cortisol deficiency

    Read More